Immune globulin intravenous (human) - Biologic Drug Details

Summary for immune globulin intravenous (human)

Tradenames:	8
High Confidence Patents:	0
Applicants:	8
BLAs:	10
Suppliers: see list	8
Recent Clinical Trials:	See clinical trials for immune globulin intravenous (human)
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for immune globulin intravenous (human)

Recent Clinical Trials for immune globulin intravenous (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	PHASE1
Washington University School of Medicine	PHASE1
University of Utah	PHASE1

See all immune globulin intravenous (human) clinical trials

Recent Litigation for immune globulin intravenous (human)

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
LIQUIDIA TECHNOLOGIES, INC. v. UNITED THERAPEUTICS CORPORATION	2025-04-21

See all immune globulin intravenous (human) litigation

Pharmacology for immune globulin intravenous (human)

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062		2037-11-06	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062		2037-06-20	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062		2037-06-12	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062		2041-11-04	DrugPatentWatch analysis and company disclosures
Adma Biologics, Inc.	BIVIGAM	immune globulin intravenous (human)	Injection	125389		2036-12-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for immune globulin intravenous (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2036-12-20	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2038-12-19	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2038-07-09	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2030-12-07	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2034-03-11	Patent claims search

International Patents for immune globulin intravenous (human)

Country	Patent Number	Estimated Expiration
Argentina	082615
Australia	2010249031
Australia	2010249033
Australia	2011252925
Australia	2012318242

Market Dynamics and Financial Trajectory for Intravenous Immune Globulin (Human)

Last updated: April 26, 2026

What is the product and where does it sit in the biopharma value chain?

Immune globulin intravenous (human), often abbreviated as IVIG, is a blood-derived biologic used for immune modulation and replacement in primary and secondary immunodeficiency states. Market demand is driven by clinical incidence (immunodeficiency, autoimmune neurologic disease, hematologic indications) and by supply constraints tied to plasma collection and fractionation capacity.

From a business perspective, IVIG is typically a high-reimbursement, commercially scaled biologic with:

• Biosimilar-like entry pressure that is structurally limited by plasma supply and process dependency (most “new” entrants rely on incremental manufacturing and supply contracts rather than direct biosimilar substitution).
• Pricing power tempered by payer oversight, tendering in some geographies, and periodic tariff and reimbursement rule changes.
• Working-capital sensitivity because inventory planning must align with variable plasma supply and seasonal/collection swings.

How do market dynamics shape demand and pricing?

Key demand drivers

IVIG use spans:

• Immune replacement in primary immunodeficiency (commonly X-linked agammaglobulinemia/Bruton’s, common variable immunodeficiency and related disorders).
• Autoimmune and inflammatory neurology including chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and others.
• Hematology and transplantation-adjacent immunomodulation in settings that may include immune thrombocytopenia (ITP), hypogammaglobulinemia, and select transplant conditioning regimens, depending on labeling and local practice.

Demand is also influenced by guideline uptake and real-world persistence, since IVIG is often dosed on repeated cycles rather than one-time administration.

Supply and cost structure

IVIG economics track the plasma supply chain:

• Plasma availability: collector throughput and donor retention determine the fractionation feedstock.
• Fractionation yield and process variability: biologics manufacturing performance affects cost per gram of IgG.
• Contracted supply and allocation: in tight supply periods, distributors and manufacturers lock in allocation terms and pricing mechanisms.

Pricing dynamics commonly show:

• Upward pressure when supply is constrained or demand increases faster than collection capacity.
• Downward pressure when new capacity releases fractionated plasma product into a softening market, or when payers implement utilization management.

Geographic dynamics

IVIG pricing and utilization vary by:

• National reimbursement models (reference pricing, tender systems, fixed margins, or diagnosis-related reimbursement).
• Hospital vs community delivery channels.
• Regulatory expectations around product interchangeability and batch-level pharmacovigilance.

In practice, manufacturers compete on availability, lead times, and payer contracting terms as much as on headline price per vial.

What is the financial trajectory typical for IVIG manufacturers?

Profit drivers

For IVIG-focused companies and large diversified biologics players, financial trajectory typically follows four levers:

1. Volume growth tied to supply expansion and contract execution
2. Operating leverage from manufacturing scale and logistics
3. Mix shifts between higher-dose access, hospital contracts, and channel mix
4. Gross margin volatility from plasma-derived input costs and any fractionation constraints

Profit risks

The financial pathway is also shaped by:

• Supply disruptions (collection shocks, fractionation downtime, regulatory holds)
• Payer reimbursement adjustments (utilization management, negotiated price ceilings)
• Foreign exchange and tariff exposure where plasma and product cross multiple markets
• Product safety events that can change prescribing behavior or trigger enhanced monitoring costs

Trajectory pattern seen in the class

Across major cycles, IVIG vendors often show:

• Sustained revenue growth when capacity expansions come online and payer contracting supports stable utilization.
• Margin compression or margin expansion based on the “plasma tightness” index and manufacturing yields.
• Reinvestment cycles in plasma collection partnerships and fractionation infrastructure.

How do investors typically evaluate IVIG performance signals?

Commercial performance metrics

• Net sales growth (volume and price separated when reported)
• Shipment volumes and geography (US vs EU vs other regions)
• Channel mix (hospital/infusion centers vs specialty pharmacy distribution)
• Payer contract cadence (annual renewals and multi-year tender awards)

Operational performance metrics

• Manufacturing yield and cost per gram
• Plasma collection volumes and collector expansion status
• Inventory and allocation management during constrained periods

Regulatory and safety signals

• Pharmacovigilance trends
• Label expansions and changes in clinical guideline recommendations
• Batch release and process validation updates

Who are the main market participants and how do they compete?

The IVIG market is dominated by large plasma-derived manufacturers and vertically integrated plasma networks. Competitive positioning typically comes from:

• Scale and guaranteed plasma supply
• Broad distribution coverage
• Contract terms and tender participation
• Product consistency and traceability

Because IVIG is plasma-derived and process-dependent, “competition” is less about one-to-one substitution and more about access to supply and payer willingness to contract.

What does the market outlook imply for revenue growth and financial stability?

Expected near-to-mid-term drivers

• Continued incidence and guideline adherence keep baseline demand steady in key indications.
• Aging populations increase autoimmune and immunodeficiency prevalence.
• Therapy migration within neurology and hematology may shift dose intensity between brands depending on payer rules and physician preferences.
• Capacity additions in plasma collection and fractionation can improve service levels, but returns depend on achieving consistent yields and contract pricing.

What could cap growth or pressure margins

• Reimbursement tightening or stricter prior authorization can limit net volume growth.
• Plasma supply fluctuations can increase unit costs and reduce shipment timing predictability.
• Safety-related restrictions can change prescribing patterns faster than supply constraints can compensate.

How does IVIG financial trajectory compare with other biologics in the immune space?

Relative to monoclonal antibodies and smaller-molecule immunology drugs, IVIG differs in two business-critical ways:

• Supply chain constraint is physical (plasma collection and fractionation) rather than purely clinical or manufacturing bottleneck.
• Demand is recurring but price negotiations are payer-centric, producing a different volatility profile than one-time or course-limited therapies.

IVIG therefore tends to behave like a steady, infrastructure-driven biologic where scale and supply reliability often matter more than trial-by-trial product novelty.

Key takeaways

• IVIG demand is recurring and payer-controlled, anchored by immune replacement and autoimmune neurologic indications.
• Market pricing and financial performance track plasma supply tightness, fractionation yield, and contract execution more than pure product differentiation.
• Revenue growth is typically supported by guideline adherence and patient volume, while margin stability depends on input costs, manufacturing performance, and reimbursement terms.
• Competitive advantage concentrates in manufacturers with reliable plasma supply partnerships, fractionation capacity, and distribution contracting discipline.

FAQs

1. Why does IVIG pricing move with plasma supply conditions?
   Because IVIG is plasma-derived, unit economics depend on plasma collection availability, fractionation yields, and supply allocation timing, which directly affect cost and contracting power.

2. Is IVIG revenue growth driven more by price or by volume?
   Both matter, but volume is often the primary driver in stable clinical settings, while pricing is constrained by reimbursement policy and payer contracting cycles.

3. How does reimbursement risk differ for IVIG versus monoclonal antibodies?
   IVIG is managed heavily through payer utilization rules due to recurring dosing, while many monoclonals face different reimbursement dynamics tied to specific trial-based labeled indications and uptake patterns.

4. What operational metrics most influence IVIG gross margin?
   Manufacturing yield, fractionation efficiency, and the cost per gram of IgG from plasma, coupled with inventory and logistics planning, drive gross margin outcomes.

5. What are the biggest threats to IVIG financial trajectory?
   Plasma supply disruptions, reimbursement tightening (utilization management or price ceilings), and safety events that change prescribing and trigger additional monitoring costs.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Plasma-Derived Products: Information for Applicants. FDA. https://www.fda.gov/
[2] European Medicines Agency. (n.d.). Plasma-derived medicinal products. EMA. https://www.ema.europa.eu/
[3] World Health Organization. (n.d.). Guidelines on the collection, processing and quality management of blood and blood components. WHO. https://www.who.int/